Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.

Molecular diagnostics are rapidly evolving, leading to increased identification of previously 'rare' clinical entities.

Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or

There are multiple new developments in the treatment of breast cancer patients with radiation therapy, as well as ongoing developments in the use of breast IMRT. Practicing clinicians need to stay informed to improve outcomes among breast cancer patients.  

There have been many recent studies that further differentiate gynecologic cancers and their management relating to pathologic features, such as molecular status.

There are many strategies for managing brain mets with radiotherapy.

Over the past five years, multiple advances in diagnostic imaging, molecular stratification, and neurosurgical and radiotherapeutic approaches have changed the multi-disciplinary management of meningioma, the most common intracranial tumor.